Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Attend this keynote webinar presentation exploring cutting-edge research on tumor-reactive T cells in lung cancer immunotherapy. Learn about innovative methods for detecting and studying tumor-infiltrating lymphocytes (TIL) in resectable lung cancers, with particular focus on non-small cell lung cancer (NSCLC) which accounts for more deaths than colon, breast, and prostate cancers combined. Discover how Dr. Kellie Smith's research team is developing groundbreaking approaches to better identify true tumor-specific T cells, distinguishing them from T cells with irrelevant antigen specificity - a fundamental limitation in current single-cell studies of intratumoral T cells. Explore the role of CD4+ helper and CD8+ effector T cells in targeting neoantigens derived from tumor somatic mutations, particularly in response to anti-PD-1 immunotherapy. Understand the significance of neoadjuvant PD-1 blockade combined with chemotherapy as the current standard of care for early-stage NSCLC patients, and examine how neoantigen-specific T cells are amplified in the periphery following treatment. Gain insights into multi-omics technologies used to study tumor-reactive T cells across various cancer types, with emphasis on molecules and pathways associated with checkpoint blockade response and resistance that are being investigated for therapeutic targeting. The presentation includes live Q&A session and offers PACE credits for registered participants, making it valuable for healthcare professionals and researchers working in cancer immunotherapy and lung cancer treatment.
